It is made available under a CC-BY 4.0 International license .

Malaria trends in districts that were targeted and not-targeted for seasonal malaria chemoprevention in children under five years of age in Guinea, 2014–2021

3	
4	Bisanzio D, ¹ Keita MS, ² Camara A, ³ Guilavogui T, ⁴ Diallo T, ² Barry H, ² Preston A, ⁵ Bangoura L, ⁶
5	Mbounga E, ⁶ Florey L, ⁸ Taton JL, ² Fofana A, ² Reithinger R^{1}
6	
7	1 RTI International, Washington D.C., U.S.A.; 2 PMI StopPalu+ Project, RTI International, Conakry,
8	Guinea; 3 National Directorate of Disease Control, Ministry of Health, Conakry, Guinea; 4 National
9	Malaria Control Program, Conakry Guinea; 5 RTI International, Fort Collins, CO, U.S.A.; 6 U.S.
10	President's Malaria Initiative, US Agency for International Development, Conakry, Guinea; 7 U.S.
11	President's Malaria Initiative, US Agency for International Development, Washington D.C., U.S.A.
12	‡ Corresponding author: Richard Reithinger, e-mail: rreithinger@yahoo.co.uk
13	

It is made available under a CC-BY 4.0 International license .

14	ABSTRACT
15	
16 17 18 19	Background Seasonal malaria chemoprevention (SMC) is one of the main interventions recommended by WHO to prevent and reduce childhood malaria. Since 2015, Guinea has implemented SMC targeting children aged 3–59 months (CU5) in districts with high and seasonal malaria transmission.
20 21 22	Objective We assessed the programmatic impact of SMC in Guinea's context of scaled-up malaria intervention programming by comparing malaria-related outcomes in 14 districts that had $(n = 8)$ or had not $(n = 6)$ been targeted for SMC.
23 24 25 26 27 28	Methods Using routine health management information system data, we calculated the district-level monthly test positivity rate (TPR) and monthly uncomplicated and severe malaria incidence for the whole population and disaggregated age groups (<5yrs and ≥5yrs of age). Changes in malaria indicators through time were analyzed by calculating the district-level compound annual growth rate (CAGR) from 2014 to 2021; we used statistical analyses to describe the time trend of the number of tested clinical cases, TPR, uncomplicated malaria incidence, and severe malaria incidence.
29 30 31 32 33 34 35 36 37	Results The CAGR of TPR of all age groups was statistically lower in SMC (median = -7.8% , range [IQR] = -9.7% , -5.5%) compared to non-SMC (median = -3.0% , IQR = -3.0% , -1.2%) districts. Similarly, the CAGR in uncomplicated malaria incidence was significantly lower in SMC (median = 1.8% , IQR = -0.9% , 3.5%) compared to non-SMC (median = 11.5% , IQR = 8.8% , 14.0%) districts. For both TPR and uncomplicated malaria incidence the observed difference was also significant age disaggregated. The CAGR of severe malaria incidence showed that all age groups experienced a decline in severe malaria in both SMC and non-SMC districts. However, this decline was significantly higher in SMC (median = -22.3% , IQR= -27.6% , -18.2%) than in non-SMC (median = -5.1% , IQR= -7.7 ; -3.6) districts for the entire population, as well as both CU5 and people over 5 years of age.
38 39 40	Conclusion Our results provide evidence to support that—even in an operational programming context—adding SMC to the comprehensive package of malaria interventions yields a positive epidemiological impact and results in greater reduction in TPR, as well as the incidence of

41 uncomplicated and severe malaria in CU5.

42

43 Key words: malaria, seasonal malaria chemoprevention, effectiveness, control, Guinea

It is made available under a CC-BY 4.0 International license .

44 INTRODUCTION

Malaria is the leading cause of morbidity and mortality in Guinea, with 2,422,445 confirmed cases and 45 1,029 deaths reported in 2021.¹ Over the past decade Guinea's National Malaria Control Programme 46 47 (NMCP)—in collaboration with bilateral, multilateral, and non-governmental partners—has scaled up 48 malaria prevention and control efforts, including rapid diagnostic tests (RDTs), artemisinin-based 49 combination therapies (ACTs), intermittent preventive treatment for pregnant women (IPTp) with 50 sulfadoxine-pyrimethamine (SP), and insecticide-treated nets (ITNs).² Additionally, in 2015, the NMCP piloted and then rolled out seasonal malaria chemoprevention (SMC) in children aged 3-59 51 months (CU5). Recommended by the WHO since 2012 for countries with seasonal malaria 52 transmission,³ SMC is the monthly administration of a single dose of sulfadoxine–pyrimethamine (SP) 53 54 and three daily doses of amodiaquine (AQ) (SP-AQ) to CU5 during the peak malaria transmission 55 season. SMC can reduce the incidence of clinical malaria in the 28 days following administration by up to 75% when effectively deployed; 4^{-7} depending on the length of the rainy season, three to five 56 cycles of SMC are conducted.⁸ As of 2021, 13 countries had adopted SMC (i.e., Benin, Burkina Faso, 57 Cameroon, Chad, Gambia, Ghana, Guinea, Guinea Bissau, Mali, Niger, Nigeria, Senegal and Togo) at 58 59 different scales of implementation.⁸

60 Clinical trials and meta-analyses have demonstrated the efficacy of SMC to reduce malaria incidence during the intervention period and parasitemia prevalence at the end of the transmission 61 season, and suggest a positive impact on all-cause mortality.⁴⁻⁷ There is also some evidence that SMC 62 results in lower prevalence of moderate to severe anemia and is associated with greater weight gain or 63 improvement of malnutrition indicators, but such effects have not always been significant across 64 studies.^{7, 9–14} Monthly administration of SP-AQ was found to be the drug regimen with the highest 65 efficacy,¹⁵⁻¹⁷ and using community health workers (CHWs) to deliver SMC was shown to be more 66 cost-effective than using facility-based nurses, immunization outreach clinics, or outreach trekking 67 teams.18,19 68

While there is strong evidence of the effect of SMC in rigorously conducted academic
 research studies, evidence on the protective effect of SMC in programmatic contexts is more limited.⁷
 ^{20, 21} This type of evaluation is challenging but very necessary—indeed, the effectiveness of
 interventions in the context of public health programs often differs from the efficacy measured in
 academic research studies, because of operational challenges when interventions are implemented at
 scale.^{22, 23}

75 The aim of the analyses presented here was to assess the programmatic impact of SMC in 76 Guinea's context of scaled-up malaria intervention programming, specifically by comparing malaria-77 related outcomes in districts that had or had not been targeted for SMC between 2015 and 2021. 78 Additionally, to do so, we wanted to use a methodological (i.e., using data routinely collected by 79 Guinea's health management information system) and an analytical approach (i.e., using the 80 compound annual growth rate) that is simple and would allow the NMCP to readily monitor SMC 81 effectiveness against standard malariometric indicators as it continues to expand the intervention 82 across the country.

83

84 METHODOLOGY

85 Study Setting

The Republic of Guinea is located in West Africa: it covers a total land area of 245,860 km² and has 86 87 an estimated population of 13.5 million people. The country is divided into 8 major administrative 88 regions, which are further divided into 38 préfectures (districts), five of which comprise the urban 89 areas around the capital city, Conakry. Districts are the main administrative unit where many of the 90 public services are planned, managed, and implemented, including for health and malaria. Guinea's 91 climate is tropical and humid with a wet (June to November) and a dry season (December to May); the 92 rainy season is followed by a peak malaria transmission season, with the highest malaria case count 93 typically observed between July to November / December, Approximately 95% of malaria cases in 94 Guinea are caused by *Plasmodium falciparum*, the principal vectors being *Anopheles gambiae*, Anopheles funestus, and Anopheles arabiensis.^{1, 24, 25} 95 96

It is made available under a CC-BY 4.0 International license .

97 SMC in Guinea

Guinea introduced SMC initially in 6 districts in 2015, scaling up to 17 districts by 2021, with four
monthly community-based SMC campaigns (cycles) conducted during the peak malaria transmission
season (generally from July to October). The NMCP implements SMC in partnership with
nongovernmental and international organizations that financially support the National Malaria
Strategic Plan and its activities. As per WHO guidance,⁸ the recommended drug regimen for SMC is
SP-AQ. CHWs (existing ones as well as ones mobilized specifically for the SMC campaign)
administer SP and the first dose of AQ to eligible children and give the remaining two daily doses of

105 AQ to the caregiver.

106 Cycles of SMC are conducted each year—once every 4 weeks during peak malaria 107 transmission season. SMC usually starts late July, but the exact starting date fluctuates every year 108 depending on several factors, including logistical considerations and rainfall. The target population for 109 SMC comprises all CU5, excluding those with known allergies to SP or AQ, those under 110 cotrimoxazole treatment, and those severely ill or experiencing a presumptive malaria episode. 111 Children 2, 11 months of age reasing one 25 mg dage of subhedening one 125 mg dage of

- 111 Children 3–11 months of age receive one 25 mg dose of sulphadoxine, one 12.5 mg dose of
- pyrimethamine, and three doses of 75 mg AQ given over the course of three consecutive days;
 children 12–59 months of age receive double doses of SP and AQ. The children's vaccination booklets
- children 12–59 months of age receive double doses of SP and AQ. The children's vaccination bookletsare consulted to help determine their age.

In teams of two, CHWs go door-to-door to every household; sometimes they organize distribution sessions at gathering venues such as markets, churches, dwellings, mosques, and fields. After explaining the SMC strategy (objective, rationale, risks, and benefits, treatment instructions) to the caregiver, they administer treatments, with any children with malaria or danger signs referred to the closest health centre. CHWs fill in forms where they indicate the number of treatments

administered in every household, and they keep updated stock management sheets. Drugs are supplied

through the Ministry of Health (MOH) to the health centres, who then allocate them to the CHWs.

Nurses in health centres are responsible for coordinating CHWs' work and for collecting SMC forms.

123 Supervisory visits are conducted by nurses and district health authorities.

124

125 Malaria Data

126 In the aftermath of the 2014–2016 Ebola outbreak, the MOH established a strategic plan to strengthen 127 its routine surveillance system, which led to the adoption of the District Health Information Software 128 (DHIS) 2, an open source, online software application as the national health information system 129 platform for monthly aggregate data from health facilities. Today this health management information 130 system (HMIS) is managed by Guinea's Système National d'Information Sanitaire (SNIS) and has 131 been rolled out nationally;²⁶ a separate instance is also currently used for weekly aggregate disease 132 surveillance and individual case surveillance of epidemic-prone diseases. The NMCP uses DHIS2 to 133 store the monthly aggregate epidemiological surveillance data collected, including all out -and 134 inpatients seen, suspected clinical malaria cases seen, suspected clinical malaria cases tested, malaria cases confirmed, and malaria cases treated.²⁶ Monthly numbers of tested clinical malaria cases, 135 136 confirmed positive clinical cases, and severe malaria are disaggregated by age group (<5 years of age 137 $[<5yrs], \ge 5$ years of ages $[\ge 5yrs]$, and pregnant women). Data for CU5 and people ≥ 5 yrs of age (PO5) 138 were downloaded for January 2014 to November 2021 from the SNIS portal; we also downloaded the

- 139 estimated catchment population of each health facility for each year.
- 140

141 Study area, Study Population, and Data Analysis

142 Analyses included 8 (Labé, Koubia, Tougue, Mali, Lelouma, Gaoual, Koundara, and Dinguiraye) and

143 6 (Boffa, Boké, Coyah, Dubreka, Forecariyah, and Fria) districts where SMC campaigns were or were

not performed from January 2014 to November 2021, respectively. We adjusted analyses to account

145 for different year of enrolment of districts in the SMC campaign (i.e., Labé and Lelouma started SMC

in 2017). The 14 study districts were among the districts supported by StopPalu and StopPalu+,

- 147 projects funded by the U.S. President's Malaria initiative and implemented by RTI International. The
- remaining districts covered by these two projects were the communes of the capital Conakry (i.e.,

It is made available under a CC-BY 4.0 International license .

Matam, Dixinn, Ratoma, Matoto, and Kaloum), which were not eligible for SMC due to their low
 malaria prevalence; these districts were therefore excluded from the analyses.

151 Among all the study districts' facilities reporting data to SNIS, we selected those that had a 152 high level of malaria data reporting completeness. Given the long study period and possible 153 difficulties in consistent data reporting, an arbitrary threshold of 10 missing months within the 2014– 154 2021 study period and no more than 3 continuously missing months per year was used to identify 155 facilities with adequate data reporting completeness. We only included public health facilities (i.e., 156 hospitals, all health centre types, and health posts) supported by StopPalu and StopPalu+. This 157 selection method identified 131 facilities of the 149 in the dataset with adequate reporting completeness. The resulting catchment population based on the selected facilities was 4,451,792 158 159 people in 2014, increasing to 5,244,844 people in 2021.

160 Using the extracted indicator data from SNIS, we calculated the monthly test positivity rate 161 (TPR) and monthly uncomplicated and severe malaria incidence at the district level for the whole 162 population, as well as disaggregated by age groups (<5yrs and $\geq 5yrs$ of age). We used statistical 163 analyses to describe the time trend of the number of tested fevers, TPR, uncomplicated malaria 164 incidence, and severe malaria incidence. The changes of these malaria indicators through time were 165 analyzed by calculating the compound annual growth rate (CAGR) from 2014 to 2021 at the district 166 level. The CAGR was calculated by dividing a time series end value by its beginning value and raising 167 the resulting figure to the inverse number of the time series years subtracting it by one. Thus, for our 168 SMC analyses, the CAGR for each malaria indicator was calculated as follows:

169
$$CAGR = \left(\frac{value\ 2021}{value\ 2014}\right)^{\frac{1}{n}} - 1$$

where n is the year of SMC implementation. Testing for differences in malaria indicator values and
 their CAGR between SMC and non-SMC districts were performed by using the Wilcoxon's signed
 rank test.²⁷

173

174 Ethical approval

This study only used existing (secondary) data that were collected for public health planning and
programming purposes. The data were only available and analyzed at the aggregate level and thus
ethical approval for the analyses was not necessary a priori.

178

179 **RESULTS**

180 SMC Coverage

In the districts included in the analyses, 8.1 million treatment doses of SP+AQ were administered to
 eligible CU5 between 2015 and 2021, resulting in an average annual programmatic SMC coverage of
 89% (range between years: 86–93%).

184

185 Number of Clinical Malaria cases Tested

186 From January 2014 to November 2021, 5,002,551 clinical malaria cases were tested in the health 187 facilities included in the study, of which 1,658,637 were CU5 (33.2%) (Table 1). Among all tested 188 clinical cases, 2,484,794 (49.7%) and 2,517,757 (50.3%) were tested in SMC and non-SMC districts, 189 respectively; in both district groups the proportion of clinical malaria in CU5 was approximately 30% 190 of all tested clinical cases (SMC districts = 29.8% vs non-SMC districts = 36.5%) (Table 1). From 191 2014 to 2021, the trend of tested clinical cases in CU5 and PO5 showed consistent increase in all 192 districts (Figure 2). The 2014–2021 CAGR of tested clinical cases for SMC districts (median = 193 12.2%, range = 4.1%, 20.6%) was significantly lower compared to that of non-SMC districts (median 194 = 19.3%; range = 12.9%, 22.2%) (Wilcoxon's test, p<0.05) (**Figure 3**). When disaggregated by age, 195 the CAGR of tested clinical cases was lower in SMC districts compared to non-SMC districts for both 196 CU5 and PO5, but it was only statistically significant for CU5 (Wilcoxon's test, p<0.05) (Figure 3). 197

198 Test Positivity Rate

It is made available under a CC-BY 4.0 International license .

199 The TPR among individuals who were tested from 2014–2021 was 56.9% (2,843,956 people), with 200 PO5 having a slightly higher TPR (57.7%) compared to CU5 (55.2%) (Table 1). When SMC was 201 accounted for, SMC districts had a lower TPR compared to non-SMC districts for each age group, 202 with the difference in TPR being 15.6 and 12.3 percentage points for CU5 and PO5, respectively 203 (Table 1). Comparing the TPR among districts from 2014 to 2021, the TPR steadily declined in SMC 204 districts, while the decline in most non-SMC districts stopped in 2019, followed by an increase during 205 2020 and 2021 (Figure 4). The TPR trend during the 2014–2021 study period showed a malaria 206 season characterized by a high transmission season between July and December (Guinea's rainy 207 season: June-November), followed by a low transmission period occurring between January and May 208 (Guinea's dry season: December–May) (Figure 5); peak malaria transmission usually occurred 209 between August and September. The TPR of SMC and non-SMC districts was similar in 2014 210 (Wilcoxon's test, p>0.05), but evolved annually to become significantly different in 2021 (Wilcoxon's 211 test, p < 0.05) (Figure 5). When disaggregated by age, for both age groups, the reduction in TPR 212 between 2014 and 2021 in SMC districts (CU5 tested fevers: median = -46.6%, range = -64.6%, -213 30.3%; PO5 tested fevers: median = -42.6\%, range = -56.2\%, -15.8\%) was more than two times higher 214 compared to the reduction in non-SMC districts (CU5 tested fevers: median = -17.1%, range = -215 37.9%, 1.1%; PO5 tested fevers: median = -18.5%, range = -56.2%, -2.8%) (Figure 6). The CAGR of 216 TPR of all age groups was statistically lower in the SMC (median = -7.8%, range = -9.7%, -5.5%) 217 compared to non-SMC (median = -3.0%, range = -3.0%, -1.2%) districts (Wilcoxon's test, p<0.05, 218 Figure 3). When disaggregated by age, the CAGR was significantly different for both CU5 (SMC 219 districts: median = -8.6%, range = -10.9%, -6.3%; non-SMC districts: median = -2.6%, range = -3.3%, 220 -1.4%) and PO5 (SMC districts: median = -7.6%, range = -9.4%, -5.2%; non-SMC districts: median = 221 -2.9%, range = -3.3%, -1.5%) when comparing the two district groups (Wilcoxon's test, p<0.05,

222 Figure 3).

223

224 Uncomplicated Malaria Incidence

225 The median malaria incidence in SMC districts was 18.5 cases per 1,000 people (IQR = 14.5, 21.6) in 226 2014 and 19.1 cases per 1,000 people (IQR = 16.4, 28.6) in 2021 (Figure 7). The median incidence in 227 non-SMC districts was 10.3 cases per 1,000 people (IQR = 9.1, 17.3) in 2014 and 26.7 cases per 1,000 228 people (IQR = 18.2, 33.7) in 2021. Thus, both SMC and non-SMC districts experienced an increase of 229 incidence from 2014 to 2021. Comparing the incidence trend among the age groups and districts, only 230 the incidence of CU5 in SMC districts showed a declining trend from 2014 to 2021. Incidence showed 231 to be statistically lower during the low transmission seasons in the SMC districts compared to non-232 SMC districts (Wilcoxon's test) (Figure 8). The CAGR in all-age malaria incidence in SMC districts 233 (median = 1.8%, range = -0.9%, 3.5%) was significantly lower compared to non-SMC districts 234 (median = 11.5%, range = 8.8%, 14.0%) (Wilcoxon's test p<0.05, Figure 3). When disaggregated by 235 age, the CAGR between SMC and non-SMC districts were significantly different for both CU5 (SMC 236 districts: median = -3.9%, range = -7.6%, -2.6%; non-SMC districts: median = 10.2%, range = 7.5%, -237 12.9%) and PO5 (SMC districts: median = 3.9%, range = 1.6%, 6.3%; non-SMC districts: median = 238 11.5%, range = 9.6%, 14%) when comparing the two district groups (Wilcoxon's test, p < 0.05, Figure 239 3).

240

241 Number of Severe Malaria Cases

242 From January 2014 to November 2021, 264,726 severe malaria cases were reported from the facilities 243 included in the study, of which 111,647 (42.2%) were from SMC districts and 153,079 (57.8%) from 244 non-SMC districts. The proportion of severe malaria in CU5 was similar in SMC districts (40,426 245 cases, 36.2%) and non-SMC districts (56,459 cases, 36.8%). The median severe malaria incidence in 246 SMC districts declined from 1.4 cases per 1,000 people (IQR = 1.1, 1.6) in 2014 to 0.2 cases per 1,000 247 people (IQR = 0.1, 0.3) in 2021, and from 0.9 cases per 1,000 people (IQR = 0.8, 1.1) to 0.6 cases per 248 1,000 people (IOR = 0.5, 0.7) in non-SMC districts (Figure 9). The incidence of severe cases was 249 higher in PO5 in both SMC districts and non-SMC districts. The reduction of severe malaria cases 250 declined in both age groups, but was significantly higher in the CU5 (Wilcoxon's test p < 0.05) (Figure

251 10). The CAGR of severe malaria incidence showed that all age groups experienced a decline in

It is made available under a CC-BY 4.0 International license .

severe malaria in both SMC and non-SMC districts. However, this decline was significantly higher in SMC (median = -22.3%, range = -27.6%, -18.2%) than in non-SMC (median = -5.1%, range = -7.7, -3.6) districts for the entire population, as well as both CU5 and PO5 (Wilcoxon's test p<0.05) (**Figure 3**).

256

257 **DISCUSSION**

258 Randomized controlled trials have shown that SMC can reduce the incidence of clinical malaria, parasitemia, anemia, severe malaria, and all-cause mortality in CU5, when effectively deployed.⁴⁻⁷ 259 260 Several studies have analyzed the effectiveness of SMC when implemented at large operational scales, 261 showing SMC protective effectiveness against clinical malaria ranging from 73-98% in CU5 at 28 and 42-days post-SMC administration, respectively.^{28, 29} However, these studies relied on large samples of 262 at-risk populations (i.e., CU5), either following case / control study designs,^{28, 29} or using nationally 263 representative surveys such as Demographic and Health Surveys or Malaria Indicator Surveys.^{30, 31} 264 265 While such approaches are certainly robust, they can be onerous, time-consuming, and costly, and may 266 not allow for continuous monitoring of the intervention across all SMC implementation areas.

267 As countries' HMIS are strengthened, there is the opportunity to increasingly use data that is 268 routinely (passively) collected by health facilities and reported by districts.^{32–36} Using district-level data from Guinea's HMIS collected between 2014–2021, we show the programmatic impact of SMC 269 270 in targeted districts, confirming the effectiveness of SMC shown in various controlled research 271 studies. Our analyses show that—in a context of strengthened case management and medium to high 272 coverage of LLINs—SMC significantly reduced the TPR, uncomplicated malaria incidence, and the 273 incidence of severe malaria in CU5 in Guinea between 2014-2021. These findings also corroborate 274 other recent analyses estimating SMC effectiveness through use of routine health information system data. Thus, in Chad, using generalized additive modelling, Richardson et al.³⁷ estimated that SMC 275 276 reduced the number of suspected and confirmed malaria in CU5 by 18% (95% CI: 6-28) and 19% 277 (95% CI: 7–29) at primary health facilities in 23 health districts during the months of SMC 278 implementation, respectively. Similarly, an evaluation of the ACCESS-SMC program using a 279 difference-in-differences approach of DHIS2 data observed a 45.0% and 55.2% reduction in malaria 280 outpatients after two years of SMC implementation in Burkina Faso and The Gambia, respectively; the 281 study also reported substantial reductions in the number of malaria inpatients and malaria hospital deaths following SMC.29 282

Interestingly, we show that the effect of SMC is particularly pronounced in the dry season 283 284 rather than the rainy season. We hypothesize that SMC results in CU5 either being fully protected 285 from infection or, if infected, only having infections with low parasitemia (which may be due to incomplete adherence to the 3-day regimen, or drug resistance).³⁸ Combined with the lower abundance 286 and density of mosquitoes during the dry season, this then results in lower transmission rates, which 287 288 leads to a lower incidence. Similar observations have been made in studies evaluating vector control interventions.³⁹ These observations do show, however, that in Guinea SMC should possibly start 289 290 earlier than in July (i.e., to have a greater effect on infection protection and transmission intensity 291 during peak transmission season), and that studies monitoring SMC impact should potentially monitor 292 effectiveness beyond the currently recommended 28–42 days post SMC administration.⁴⁰

293 Moreover, unlike prior controlled academic research and other studies, our analyses also 294 demonstrate an effect of SMC administered to CU5, albeit lower, on PO5, specifically for TPR, 295 uncomplicated malaria incidence, and severe malaria incidence. Such effect seems plausible, given 296 that—even in a context of decreasing malaria prevalence such as Guinea¹—CU5 still represent a large 297 proportion of all cases (i.e., 55.2% for the 2014–2021 study period; **Table 1**) and, thus, a substantial 298 proportion of the human reservoir infecting anopheline mosquitoes. Any significant intervention effect 299 reducing the CU5 Plasmodium reservoir will lower transmission intensity and, thus, spill over and 300 reduce malariometric indicators in PO5.

As support continues for malaria elimination and additional means for malaria control are
 introduced (e.g., vaccines), alternative methods for measuring impact must be explored outside trial
 settings as controlled and observational research studies to investigate effectiveness at scale are very
 costly. Multiple impact evaluations and approaches that address gaps or biases in data and

It is made available under a CC-BY 4.0 International license .

305 triangulating between data sources strengthens the plausibility of program impact. We used the CGAR 306 as an analytical method. The CAGR is a commonly used methodology in the field of economics to 307 describe changes in (economic) growth from the beginning to the end of a timeseries. The advantage 308 of using CAGR compared to other analytical approaches—such as average annualized rates—is that 309 the resulting estimate is not affected by fluctuations within the time series that could produce 310 misleading results. The CAGR methodology has previously been used in the public health field to evaluate health care systems and effects of interventions through time.⁴¹⁻⁴³ An additional advantage of 311 312 the approach is that, because it is algebra-based, it does not require advanced data analytics or 313 modelling expertise, and thus can be applied by program personnel with a basic understanding of 314 calculus (e.g., in MS Excel worksheets, or even DHIS2).

315 Because SMC is consistently proving to be a high-coverage and effective intervention, 316 several countries with seasonal malaria transmission outside of the Sahel are now piloting SMC to be included in their malaria intervention package (e.g., Uganda⁴⁴ and Mozambique⁴⁵). WHO recently 317 amended the SMC guidelines to give countries flexibility to change the SMC regimen (e.g., by adding 318 319 additional SMC cycles to cover longer peak transmission seasons, or by including older age groups). 320 Such step is likely going to increase the effect of SMC even further, either in CU5 (if additional SMC 321 cycles are added) or in older age groups (if older age groups are covered with SMC)-indeed recent studies in Burkina Faso, Mali and Senegal seem to corroborate this.^{46–48} Moreover, there is increased 322 interest to use SMC campaigns to integrate or leverage other health interventions, 49-51 the rationale 323 324 being that (1) other health interventions that may not have as high population acceptance or coverage 325 as SMC would benefit from the high acceptance and coverage of SMC; and (2) cost-efficiencies 326 would be obtained, since combining intervention planning, implementation and monitoring would 327 result in various economies of scale (e.g., training of health workers, transport costs, limiting health 328 workers' time to implement campaigns rather than providing health services).

329

330 Limitations

331 Several potential caveats of our analyses should be highlighted. First, our analyses did not adjust for 332 intervention coverage, either for SMC or other malaria interventions such as LLINs. Thus, we assume 333 that programmatic coverage, use of, and adherence to these interventions is relatively homogenous and 334 that the only difference in overall malaria intervention coverage between the two sets of districts 335 included in our analyses is the administration of SMC to CU5. Post-SMC round assessments 336 consistently showed programmatic coverage of 82–93% across districts included in our analyses 337 (Table 1). Moreover, as per 2021 Malaria Indicator Survey data, LLIN use in CU5 in households with 338 at least 1 LLINs was 60.4% in survey enumeration areas in SMC districts, compared to 65.6% for non-339 SMC districts.

340 Second, using routine HMIS data for impact evaluations can be problematic due to internal 341 validity, completeness, and potential bias in estimates of effect, and caution must be exercised in 342 interpreting analytical findings.³² Additionally, challenges with HMIS data are that they are dependent 343 on the proportion of infected individual cases seeking treatment for malaria at public sector health 344 facilities; the proportion of patients seeking care who are parasitologically diagnosed; and facilities 345 reporting all suspected and confirmed malaria cases consistently over time. Thus, for example, even 346 though SMC was implemented in Guinea since 2015, an increase in the number of fevers was 347 observed in CU5, suggesting a lack of impact of SMC. However, during this period, changes in access 348 to health services occurred, such as improvement in malaria case detection and diagnosis at facility 349 and community levels, removal of user access fees for CU5 and pregnant women, and improvement in 350 the availability of malaria diagnostic and case management commodities. We controlled for such bias 351 by excluding health facilities with incomplete reporting (i.e., facilities with 10 months of missing data 352 throughout the study period, and no more than 3 continuously missing months per year), and note that 353 these facilities were evenly spread across SMC and non-SMC districts. We also note that our analyses 354 of the SMC effect in CU5 was consistently observed across all malariometric indicators included in 355 our analysed.

Third, malaria testing to identify cases in Guinea is largely RDT-based. Although used tests have a high sensitivity and specificity, it is possible that low parasitemic and asymptomatic infections

It is made available under a CC-BY 4.0 International license .

were missed. It is unlikely, however, that such infections would have clustered in a specific
 spatiotemporal pattern across SMC compared to non-SMC districts, and, thus, would unlikely change
 our findings and conclusions.

Fourth, we delineated our analyses to district boundaries, rather than a defined area size (e.g., 25 km²). This was done because routinely collected HMIS data gets aggregated at that level and districts are the lowest administrative unit in Guinea that plan, implement and monitor malaria programming; any response to an increase in malaria cases would occur at district level.

Finally, spatial analyses performed using arbitrary spatial divisions such as district
administrative boundaries can be affected by the modifiable areal unit problem.^{52, 53} For example,
cases that were reported at a health facility in a given district could stem from households in a
different district, and therefore, bias district-level malaria HMIS data. Thus, the possibility remains

that cases got infected outside of their district (e.g., during travel).

370

371 CONCLUSION

372 Our study provides evidence to support that—even in an operational programming context—adding

373 SMC to the comprehensive package of malaria interventions yields a positive epidemiological impact

and results in a greater reduction in TPR, malaria incidence and hospitalizations in CU5 than when

375 implementing an intervention package without SMC. We also show that the use of routine HMIS data

376 represents a viable method for assessing the epidemiological impact of public health interventions in

the absence of trial studies, household surveys, and extensive covariate data. Further studies on the

378 effectiveness of SMC at scale should use data obtained from a wider range of sources.

It is made available under a CC-BY 4.0 International license .

379 Acknowledgements

We thank Guinea's Ministry of Health staff who participated in SMC programmatic efforts, as well asthe communities in the study districts for their collaboration.

382 Funding

- 383 Financial support for this study was provided by the U.S. President's Malaria Initiative through the
- 384 U.S. Agency for International Development StopPalu (Cooperative Agreement Number: AID-675-A-
- 385 13-00005) and StopPalu+ (Cooperative Agreement Number: 72067518CA000015) programs. The
- 386 findings and conclusions in this report are those of the author(s) and do not necessarily represent the
- 387 official position of the U.S. Agency for International Development.

388 Competing Interest

389 None declared.

390 Patient and public involvement

- 391 Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination
- 392 plans of this research.

It is made available under a CC-BY 4.0 International license .

393 **REFERENCES**

394		
395 396	1.	Ministry of Health. Annual Bulletin of the National Malaria Control Program 2020. Ministry of Health, Conakry, 2021.
397	2.	NMCP. National Strategic Plan 2018–2022. Ministry of Health, Conakry, 2018.
398 399	3.	WHO. Seasonal malaria chemoprevention for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. WHO, Geneva, 2012.
400 401	4.	Wilson AL, IPTc Taskforce IP. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One 2011; 6:
402		e16976.
403 404 405	5.	Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2012; 2: CD003756.
406 407 408	6.	Cairns M, Roca-Feltrer A, Garske T, Wilson A, Diallo D, Milligan P, Ghani A, Greenwood AM. Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nature 2012; 3: 881.
409 410	7.	WHO. Guidelines for malaria. WHO, Geneva, 2022. <u>https://www.who.int/teams/global-</u> malaria-programme/guidelines-for-malaria
411 412 413	8.	WHO. Updated WHO recommendations for malaria chemoprevention among children and pregnant women. WHO, Geneva, 2022. <u>https://www.who.int/news/item/03-06-2022-Updated-WHO-recommendations-for-malaria-chemoprevention-among-children-and-pregnant-women</u>
414 415 416 417 418	9.	Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Diawara H, Conaré T, Djimde A, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011; 8: e1000407.
419 420 421 422 423 424	10.	Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011; 8: e1000408.
425 426 427 428 429	11.	Cissé B, Sokhna C, Boulanger D, Milet J, Bâ el H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebocontrolled, double-blind trial. Lancet 2006; 367: 659–667.
430 431 432 433	12.	Diawara F, Steinhardt LC, Mahamar A, Traore T, Kone DT, Diawara H, Kamate B, Kone D, Diallo M, Sadou A, Mihigo J, Sagara I, Djimde AA, Eckert E, Dicko A. Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali. Malaria J 2017; 16:325.
434 435 436	13.	Kweku M, Liu D, Adjuik M, Binka F, Seidu M, Greenwood B, Chandramohan D. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo-controlled trial. PLoS One 2008; 3: e4000.
437 438 439 440	14.	Ntab B, Cissé B, Boulanger D, Sokhna C, Targett G, Lines J, Alexander N, Trape JF, Simondon F, Greenwood BM, Simondon KB. Impact of intermittent preventive anti-malarial treatment on the growth and nutritional status of preschool children in rural Senegal (West Africa). Am J Trop Med Hyg 2007; 77: 411–417.
441 442	15.	Sokhna C, Cissé B, Bâ el H, Milligan P, Hallett R, Sutherland C, Gaye O, Boulanger D, Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF. A trial of the efficacy,

It is made available under a CC-BY 4.0 International license .

443 444		safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One 2008; 3: e1471.					
445 446 447	16.	Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, Milligan P, Greenwood B. A candomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One 2010; 5: e11225.					
448 449 450 451 452	17.	Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, Rosenthal PJ, Sutherland C, Nosten F, Ouedraogo JB. Randomized noninferiority trial of dihydroartemisininpiperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother 2015; 59: 4387–4396.					
453 454 455	18.	Patouillard E, Conteh L, Webster J, Kweku M, Chandramohan D, Greenwood B. Coverage, adherence and costs of intermittent preventive treatment of malaria in children employing different delivery strategies in Jasikan, Ghana. PLoS One 2011; 6: e24871.					
456 457 458 459	19.	Bojang KA, Akor F, Conteh L, Webb E, Bittaye O, Conway DJ, Jasseh M, Wiseman V, Milligan PJ, Greenwood B. Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial. PLoS Med 2011; 8: e1000409.					
460 461 462	20.	Buffet PA, Briand V, Renia L, Thellier M, Danis M, Mazier D. Intermittent preventive antimalarial treatment to children (IPTc): firebreak or fire trap? Trends Parasitol 2008; 24: 482–485, discussion 485–486.					
463 464 465	21.	Beeson JG, Rogerson SJ, Mueller I, Richards JS, Fowkes FJ. Intermittent preventive treatment to reduce the burden of malaria in children: new evidence on integration and delivery. PLoS 2011; Med 8: e1000410.					
466 467	22.	Barreto ML. Efficacy, effectiveness, and the evaluation of public health interventions. J Epidemiol Community Health 2005; 59: 345–346.					
468 469 470	23.	The malERA Refresh Consultative Panel on Health Systems and Policy Research: An updated research agenda for health systems and policy research in malaria elimination and eradication. PLoS Medicine 2017; 14: e1002454.					
471 472 473 474	24.	Beavogui AH, Delamou A, Camara BS, Camara D, Kourouma K, Camara R, Sagara I, Lama EK, Djimde A. Prevalence of malaria and factors associated with infection in children aged 6 months to 9 years in Guinea: results from a national cross-sectional study. Parasite Epidemiol Control 2020;11: e00162.					
475 476 477 478	25.	Sayre D, Camara A, Barry Y, Deen TB, Camara D, Dioubaté M, Camara I, Keita K, Diakité N, Lo Y, Bah I, Camara HF, Condé MS, Fofana A, Sarr A, Lama E, Irish S, Plucinski M. Combined Epidemiologic and Entomologic Survey to Detect Urban Malaria Transmission, Guinea, 2018. Emerg Infect Dis. 2021; 27: 599-602.					
479 480 481 482 483 484	26.	Reynolds E, Martel LD, Bah MO, Bah M, Bah MB, Boubacar B, Camara N, Camara YB, Corvil S, Diallo BI, Diallo IT, Diallo MK, Diallo MT, Diallo T, Guilavogui S, Hemingway- Foday JJ, Hann F, Kaba A, Kaba AK, Kande M, Lamarana DM, Middleton K, Sidibe N, Souare O, Standley CJ, Stolka KB, Tchwenko S, Worrell MC, MacDonald PDM. Implementation of DHIS2 for Disease Surveillance in Guinea: 2015-2020. Front Public Health 2022;9: 761196.					
485 486	27.	Hollander M, Wolfe DA. <i>Nonparametric Statistical Methods</i> . New York: John Wiley & Sons, 1973.					
487 488 489 490 491	28.	Cairns M, Ceesay SJ, Sagara I, Zongo I, Kessely H, Gamougam K, Diallo A, Ogboi JS, Moroso D, Van Hulle S, Eloike T, Snell P, Scott S, Merle C, Bojang K, Ouedraogo JB, Dicko A, Ndiaye JL, Milligan P. Effectiveness of seasonal malaria chemoprevention (SMC) treatment when SMC is implemented at scale: case-control studies in 5 countries. PLoS Medicine 2021; 18: e1003727.					
492 493	29.	ACCESS-SMC Partnership. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet 2020; 396: 1829–40.					

494 495	30.	Druetz T. Evaluation of direct and indirect effects of seasonal malaria chemoprevention in Mali. Scientific Reports 2018; 8: 8104.
496 497 498 499	31.	de Cola MA, Sawadogo B, Richardson S, Ibinaiye T, Traoré A, Compaoré CS, Oguoma C, Oresanya O, Tougri G, Rassi C, Roca-Feltrer A, Walker P, Okell LC. Impact of seasonal malaria chemoprevention on prevalence of malaria infection in malaria indicator surveys in Burkina Faso and Nigeria. BMJ Global Health 2021; 7: e008021.
500 501 502	32.	Rowe AK, Kachur SP, Yoon SS, Lynch M, Slutsker L, Steketee RW. Caution is required when using health facility based data to evaluate the health impact of malaria control efforts in Africa. Malar J 2009; 8: 1–3.
503 504	33.	Afrane YA, Zhou G, Githeko AK, Yan G. Utility of health facility-based malaria data for malaria surveillance. PLoS One 2013; 8: e54305.
505 506 507	34.	Ashton RA, Bennett A, Yukich J, Bhattarai A, Keating J, Eisele TP. Methodological considerations for use of routine health information system data to evaluate malaria program impact in an era of declining malaria transmission. Am J Trop Med Hyg 2017; 97: 46–57.
508 509	35.	WHO. Analysis and Use of Health Facility Data: Guidance for Malaria Programme Managers. World Health Organization, Geneva, 2018.
510 511 512	36.	Wagenaar BH, Sherr K, Fernandes Q, Wagenaar AC. Using routine health information systems for well-designed health evaluations in low- and middle-income countries. Health Policy Planning 2016; 31: 129–135
513 514 515 516	37.	Richardson S, Moukenet A, Diar MSI, de Cola MA, Rassi C, Counihan H, Roca-Feltrer A. Modeled Impact of Seasonal Malaria Chemoprevention on District-Level Suspected and Confirmed Malaria Cases in Chad Based on Routine Clinical Data (2013-2018). Am J Trop Med Hug. 2021; 105: 1712-1721
510 517 518	38.	Chotsiri P, White NJ, Tarning. Pharmacokinetic considerations in seasonal malaria chamoprevention. Trends Paresitel. 2022; 38: 673–682
519 520	39.	Fullman N, Burstein R, Lim SS, Medlin C, Gakidou E. Nets, spray or both? The effectiveness of insecticide-treated nets and indoor residual spraying in reducing malaria morbidity and
521 522 523	40.	WHO (2022) Malaria chemoprevention efficacy study protocol. World Health Organization, Geneva, 2022.
524 525 526	41.	Hwang J, Shen JJ, Kim SJ, Chun SY, Kim PC, Lee SW, Byun D, Yoo JW. Opioid use disorders and hospital palliative care among patients with gastrointestinal cancers: ten-year trend and associated factors in the US from 2005 to 2014. Medicine 2020; 99: e20723.
527 528 529 530	42.	Joo MK, Yoo JW, Mojtahedi Z, Kim P, Hwang J, Koo JS, Kang HT, Shen JJ. Ten-year trends of utilizing palliative care and palliative procedures in patients with gastric Cancer in the United States from 2009 to 2018-a nationwide database study. BMC Health Services Research 2022; 22: 20.
531 532	43.	Moses H, Matheson DH, Dorsey ER, George BP, Sadoff D, Yoshimura S. The anatomy of health care in the United States. JAMA 2013; 310: 1947–1964.
533 534 535 536 537	44.	Nuwa A, Baker K, Bonnington C, Odongo M, Kyagulanyi T, Bwanika JB, Richardson S, Nabakooza J, Achan J, Kajubi R, Odong DS, Nakirunda M, Magumba G, Beinomugisha G, Marasciulo-Rice M, Abio H, Rassi C, Rutazaana D, Rubahika D, Tibenderana J, Opigo J. A non-randomized controlled trial to assess the protective effect of SMC in the context of high parasite resistance in Uganda. Malar J. 2023; 22: 63.
538 539 540 541	45.	Baker K, Aide P, Bonnington CA, Rassi C, Richardson S, Roca-Feltrer A, Rodrigues M, Sitoe M, Pulido Tarquino IA, Enosse S, McGugan C, de Carvalho EA, Saute F, Mayor Aparicio AG, Candrinho B (2022) Feasibility, Acceptability, and Protective Efficacy of Seasonal Malaria Chemoprevention Implementation in Nampula Province, Mozambique: Protocol for a
542 543	46.	Hybrid Effectiveness-Implementation Study. JMIR Res Protoc. 11: e36403. Cissé B, Ba EH, Sokhna C, NDiaye JL, Gomis JF, Dial Y, Pitt C, NDiaye M, Cairns M, Faye
544 545		E, NDiaye M, Lo A, Tine R, Faye S, Faye B, Sy O, Konate L, Kouevijdin E, Flach C, Faye O, Trape JF, Sutherland C, Fall FB, Thior PM, Faye OK, Greenwood B, Gaye O, Milligan P.

It is made available under a CC-BY 4.0 International license .

546 547 548	47.	Effectiveness of seasonal malaria chemoprevention in children under 10 years of age in Senegal: a stepped-wedge cluster randomised trial. PLoS Medicine 2016; 13: e1002175. Ndiaye JLA, Ndiaye Y, Ba MS, Faye B, Ndiaye M, Seck A, Tine R, Thior PM, Atwal S,
549 550 551		Beshir K, Sutherland C, Gaye O, Milligan P. Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: a cluster randomised trial. PLoS Medicine 2019; 16: e1002762.
552 553 554 555	48.	Bâ EH, Pitt C, Dial Y, Faye SL, Cairns M, Faye E, Ndiaye M, Gomis JF, Faye B, Ndiaye JL, Sokhna C, Gaye O, Cissé B, Milligan P. Implementation, coverage and equity of large-scale door-to-door delivery of seasonal malaria chemoprevention (SMC) to children under 10 in Senegal. Scientific Reports 2018; 8: 5489.
556 557 558 559	49.	Bazant E, McPhillips-Tangum C, Shrestha SD, G S P, Khera A, Nic Lochlainn L, Habtamu E, Patel VI, Muhire G, Saarlas KN. Promising practices for the collaborative planning of integrated health campaigns from a synthesis of case studies. BMJ Glob Health 2022; 7: e010321.
560 561 562 563 564	50.	Oresanya O, Phillips A, Okereke E, Ahmadu A, Ibinaiye T, Marasciulo M, Ward C, Adesoro O, Mohammed R, Nikau J, Isokpunwu CO, Inname MA, Counihan H, Baker K, Maxwell K, Smith H. Co-implementing vitamin A supplementation with seasonal malaria chemoprevention in Sokoto State, Nigeria: a feasibility and acceptability study. BMC Health Serv Res. 2022; 22: 871
565 566 567 568	51.	Keita MS, Camara A, Daffe M, Fofana A, Balde M, Diallo T, Barry H, Fitch E, Taton JL, Bangoura L, Mbounga E, Reithinger R. Integrating nutrition assessments and seasonal malaria chemoprevention: Results from a mixed-methods feasibility study in Guinea. Trop Med Int Health 2023; 28: 571–575.
569 570	52.	Wong DW. The modifiable areal unit problem (MAUP). In: WorldMinds: geographical perspectives on 100 problems; 2004. Springer, Dordrecht, 2004.
571 572 573	53.	Alegana VA, Atkinson PM, Wright JA, et al. Estimation of malaria incidence in northern Namibia in 2009 using Bayesian conditional- autoregressive spatial- temporal models. Spat Spatiotemporal Epidemiol 2013; 7: 25–36.
574 575 576 577	54.	Gilmartin C, Nonvignon J, Cairns M, Milligan P, Bocoum F, Winskill P, Moroso D, Collins D. Seasonal malaria chemoprevention in the Sahel subregion of Africa: a cost-effectiveness and cost-savings analysis. Lancet Glob Health 2019; 9: e199–e208.
577		

It is made available under a CC-BY 4.0 International license .

578 Tables and figures

It is made available under a CC-BY 4.0 International license .

Age Group	All districts		SMC di	stricts	Non-SMC district	
	Tested	Positive (%)	Tested	Positive (%)	Tested	Positive (%)
<5yrs age group	1,658,637	915,831 (55.2%)	739,403	344,420 (46.6%)	919,234	571,411 (62.2%)
≥5yrs age group	3,343,914	1,928,125 (57.7%)	1,745,391	904,818 (51.8%)	1,598,523	1,023,307 (64.1%)
Total	5,002,551	2,843,956 (56.9%)	2,484,794	1,249,238 (50.3%)	2,517,757	1,594,718 (63.4%)

Table 1. Number of tested fevers, positive tests, and positive rate divided by age group and	SMC
coverage during the study period (January 2014 – November 2021).	



Figure 1. Districts covered by the StopPalu and StopPalu+ in which SMC was performed.

Figure 2. Number of tested fevers in SMC and non-SMC districts per age group and year. Plots show tested fevers for all-age groups, <5yrs age group, and ≥5yrs age group in SMC (A) and non-SMC districts (B)



It is made available under a CC-BY 4.0 International license .

Figure 3. CAGR of tested fevers (A), TPR (B), malaria incidence (C), and severe malaria cases (D) in SMC districts and non-SMC districts from 2014 to 2021. The '*' symbol represents a significant difference (p<0.05, Wilcoxon's test) between CAGR values of SMC district and non-SMC districts.



It is made available under a CC-BY 4.0 International license .



Figure 4. TPR of tested fevers in SMC districts and non-SMC districts per age group and year. Plots show TPR for all-age groups, <5yrs age group, and \geq 5yrs age group in SMC (A) and non-SMC districts (B)



Figure 5. Boxplot of annual TPR of SMC districts and non-SMC districts from January 2014 to November 2021 for all age groups, <5 age group, and ≥ 5 age group.

Figure 6. Boxplot comparing TPR of SMC (left column) and non-SMC (right column) districts by age group of 2014 to November 2021 for <5 yrs and \geq 5 yrs age group. The '*' symbol represents a significant difference (p<0.05, Wilcoxon's test) between SMC and non-SMC districts.



It is made available under a CC-BY 4.0 International license .



Figure 7. Malaria incidence in SMC (A) and non-SMC (B) districts per age group and year. Plots show malaria incidence for all-age groups, <5yrs age group, and ≥5 yrs age group in SMC (A) and non-SMC districts (B)

Figure 8. Boxplot of malaria incidence of SMC districts and non-SMC districts from January 2014 to November 2021 for all age groups, <5 yrs age group, and ≥5 yrs age group, by year.



It is made available under a CC-BY 4.0 International license .





It is made available under a CC-BY 4.0 International license .



Figure 10. Incidence of severe malaria cases in SMC (A) and non-SMC (B) districts per age group and year. Plots show severe malaria incidence for all-age groups, <5yrs age group, and $\geq 5yrs$ age group in SMC (A) and non-SMC districts (B)

It is made available under a CC-BY 4.0 International license .

Figure 11. Boxplot comparing severe malaria cases per 1,000 people in SMC (left column) and non-SMC (right column) districts per age group of 2014 to April 2019 <5 yrs age group and \geq 5 yrs age group. The '*' symbol represents a significant difference (p<0.05, Wilcoxon's test) between SMC district and non-SMC districts.

